XtalPi, Pierre Fabre Partner on AI Cancer Drugs

The Hong Kong-listed firm and the French drugmaker will combine AI and lab robotics to discover oncology small molecules.

Updated on Nov. 9, 2026 in Cancer

XtalPi, Pierre Fabre Partner on AI Cancer Drugs

Laboratoires Pierre Fabre and XtalPi Holdings announced a partnership on Monday to use artificial intelligence and automated lab robotics in the search for cancer drugs. XtalPi will design new small-molecule drugs from scratch while Pierre Fabre selects promising compounds and handles clinical and commercial development.

Why it matters

The companies are targeting complex molecular targets that have historically been hard for drugs to address. The deal adds to Pierre Fabre's research and development roadmap and strengthens its drug discovery capabilities.

XtalPi reports an approximately 85% success rate for its robotic compound synthesis, a measure of chemistry output rather than clinical efficacy. The number of programs covered and the expected timing of first clinical candidates have not been disclosed.

The players

XtalPi Holdings

A Shenzhen-based AI drug discovery company listed in Hong Kong under the stock code 2228.HK, known for combining machine learning with automated laboratory synthesis.

Laboratoires Pierre Fabre

A France-based pharmaceutical company headquartered in Castres that develops prescription medicines and dermatology products.

The details

Under the agreement, XtalPi will design small-molecule drugs using its AI and robotics platform, which it has offered to outside customers since 2023. Pierre Fabre will choose and advance promising compounds, and the companies agreed to an upfront payment, milestone payments, and a share of future economic benefits.

Timeline

  1. 2023: XtalPi began offering its automated synthesis system to outside customers.

  2. Monday, Nov. 9, 2026: Laboratoires Pierre Fabre and XtalPi announced the partnership in a joint statement.

Health Landscape

The deal extends the use of AI-driven automated synthesis platforms from a service sold to outside customers into a co-development model with a major pharmaceutical company. It follows a broader industry move toward computationally designed small molecules for oncology.

For patients, the partnership is at an early discovery stage, and no timeline for clinical candidates has been set. Any resulting therapies would still need to pass clinical trials before becoming available.

The takeaway

AI-driven drug design is moving from laboratory tools toward shared development partnerships with established drugmakers. Readers should watch for clinical candidates, which will be the first real test of whether computational synthesis translates into treatments.

Further reading

For more on the disease area, see Cancer.